Seize the day: Newborn screening for SMA

American Journal of Medical Genetics, Part A

Volumn 152, Issue 7, 2010, Pages 1605-1607

  Swoboda, Kathryn J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

CHILD; HUMAN; INFANT; INTERDISCIPLINARY COMMUNICATION; MUSCLE ACTION POTENTIAL; NEWBORN; NEWBORN SCREENING; NOTE; PALLIATIVE THERAPY; PRIORITY JOURNAL; SPINAL MUSCULAR ATROPHY; ADVISORY COMMITTEE; ANIMAL; COOPERATION; DISEASE MODEL; GOVERNMENT; HEALTH CARE PLANNING; MOUSE; MUSCULAR ATROPHY, SPINAL;

ADVISORY COMMITTEES; ANIMALS; COOPERATIVE BEHAVIOR; DISEASE MODELS, ANIMAL; FEDERAL GOVERNMENT; HEALTH PLANNING GUIDELINES; HUMANS; INFANT, NEWBORN; MICE; MUSCULAR ATROPHY, SPINAL; NEONATAL SCREENING;

EID: 77954138061     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.33519     Document Type: Note

References (20)

1. AAP Newborn Screening Task Force. 2000. Serving the family from birth to the medical home. Newborn Screening: A blueprint for the future. A call for a national agenda on state newborn screening programs. Pediatrics 106:389-427.
2. Alexander D, van Dyck PC. 2006. A vision of the future of newborn screening. Pediatrics 117:350-354.
3. Bromberg MB, Swoboda KJ. 2002. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 25:445-447.
4. Butchbach MER, Le TT Burghes AHM. 2004. Protective effects of butyrate analogues and prodrugs on a mouse model for spinal muscular atrophy. Washington, DC: Society for Neuroscience. Prog. No. 226.17. Abstract Viewer/Itinerary Planner.
5. Butchbach MER, Simard LR, Burghes AHM. 2005. SMN independent amelioration of mouse spinal muscular atrophy by butyrate prodrugs. Washington, DC: Society for Neuroscience. Prog. No. 338.7. Abstract Viewer/Itinerary Planner.
6. Butchbach ME, Rose FF Jr, Rhoades S, Marston J, McCrone JT, Sinnott R, Lorson CL. 2010a. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem Biophys Res Commun 391:835-840 [Epub November 27, 2009].
7. Butchbach ME, Singh J, Thorsteinsdóttir M, Saieva L, Slominski E, Thurmond J, Andrésson T, Zhang J, Edwards JD, Simard LR, Pellizzoni L, Jarecki J, Burghes AH, Gurney ME. 2010b. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 19:454-467.
8. Calonge N, Green NS, Rinaldo P, Lloyd-Puryear M, Dougherty D, Boyle C, Watson M, Trotter T, Terry SF, Howell RR, for the Advisory Committee on Heritable Disorders in Newborns and Children. 2010. Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children. Genet Med 12:153-159.
9. Crawford TO. 2004. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord 14:456-460 [review].
10. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT MoralesPR, Rich MM, Burghes AH,Kaspar BK. 2010. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28:271-274 [Epub February 2, 2010].
11. Howell RR. 2006. Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Ment Retard Dev Disabil Res Rev 12:313-315.
12. Lewelt AJ, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, Acsadi G, D'Anjou G, Elsheikh B, Reyna SP, Schroth MK, Maczulski J, Elovic E, Swoboda KJ. 2010. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve (in press).
13. McGovern VL, Gavrilina TO, Beattie CE, Burghes AH. 2008. Embryonic motor axon development in the severe SMA mouse. Hum Mol Genet 17:2900-2909.
14. Murray LM, Lee S, Bäumer D, Parson SH, Talbot K, Gillingwater TH. 2010. Pre-symptomatic development of lower motor neuron connectivity in a severe mouse model of spinal muscular atrophy. Hum Mol Genet 19:420-433 [Epub November 2, 2009].
15. Narver HL, Kong L, Burnett BG, Choe DW, Bosch-Marcé M, Taye AA, Eckhaus MA, Sumner CJ. 2008. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol 64:465-470.
16. Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, De Vivo DC, Kaufmann P. 2007. The changing natural history of spinal muscular atrophy type 1. Neurology 69:1931-1936.
17. Pearn J. 1978. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15:409-413. (Pubitemid 9093440)
18. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, Conlan T, Schmalz B, Montgomery L, Ziegler K, Noonan C. 2010. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet Part A 152A:(in press).
19. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB. 2005. Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function. Ann Neurol 57:704-712.
20. Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G,D'Anjou G, Krosschell KJ, Reyna SP, Schroth MK, Scott CB, Simard LR. 2007. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol 22:957-966 (review).